{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:54:33Z","timestamp":1793987673996,"version":"4.8.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.atherosclerosis.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T20:46:02Z","timestamp":1653079562000},"page":"92-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology"],"prefix":"10.1016","volume":"349","author":[{"given":"Marlys L.","family":"Koschinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Boffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib1","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2174\/0929867325666180316121015","article-title":"The role of (modified) lipoproteins in vascular function: a duet between monocytes and the endothelium","volume":"26","author":"Schnitzler","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"Suppl","key":"10.1016\/j.atherosclerosis.2022.04.001_bib2","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1194\/jlr.R800074-JLR200","article-title":"The role of oxidized phospholipids in atherosclerosis","volume":"50","author":"Berliner","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-021-00618-8","article-title":"Innate immune detection of lipid oxidation as a threat assessment strategy","author":"Zhivaki","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1050-1738(01)00098-6","article-title":"Evidence for a role of phospholipid oxidation products in atherogenesis","volume":"11","author":"Berliner","year":"2001","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00041433-200310000-00002","article-title":"Oxidized phospholipids as modulators of inflammation in atherosclerosis","volume":"14","author":"Leitinger","year":"2003","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1194\/jlr.R400001-JLR200","article-title":"The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL","volume":"45","author":"Navab","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib7","doi-asserted-by":"crossref","first-page":"12741","DOI":"10.1073\/pnas.0605457103","article-title":"Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids","volume":"103","author":"Gargalovic","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib8","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1194\/jlr.P030890","article-title":"Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions","volume":"53","author":"van Dijk","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib9","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1161\/ATVBAHA.121.316154","article-title":"Accumulation of plasma-derived lipids in the lipid core and necrotic core of human atheroma: imaging mass spectrometry and histopathological analyses","volume":"41","author":"Nakagawa","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib10","doi-asserted-by":"crossref","first-page":"38503","DOI":"10.1074\/jbc.M203318200","article-title":"Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36","volume":"277","author":"Podrez","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib11","doi-asserted-by":"crossref","first-page":"38517","DOI":"10.1074\/jbc.M205924200","article-title":"A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions","volume":"277","author":"Podrez","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib12","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm1626","article-title":"Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype","volume":"13","author":"Podrez","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084488","article-title":"Phosphoproteomic analysis of platelets activated by pro-thrombotic oxidized phospholipids and thrombin","volume":"9","author":"Zimman","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1172\/JCI4533","article-title":"Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins","volume":"103","author":"Horkko","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1172\/JCI118853","article-title":"Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma","volume":"98","author":"Palinski","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib16","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1172\/JCI8472","article-title":"Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity","volume":"105","author":"Shaw","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib17","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1074\/jbc.M108860200","article-title":"Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation","volume":"277","author":"Friedman","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib18","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1073\/pnas.96.11.6353","article-title":"Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition","volume":"96","author":"Chang","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib19","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1084\/jem.20031763","article-title":"Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory","volume":"200","author":"Chang","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.carrev.2011.08.001","article-title":"The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization","volume":"13","author":"Fefer","year":"2012","journal-title":"Cardiovasc. Revascularization Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jacbts.2017.02.004","article-title":"Lipoprotein(a) associated molecules are prominent components in plasma and valve leaflets in calcific aortic valve stenosis","volume":"2","author":"Torzewski","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-018-0198-8","article-title":"Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice","volume":"558","author":"Que","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib23","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1161\/01.CIR.0000141728.23033.B5","article-title":"High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial","volume":"110","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib24","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/ATVBAHA.116.308761","article-title":"Oxidized phospholipids and risk of calcific aortic valve disease: the copenhagen general population study","volume":"37","author":"Kamstrup","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib25","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib26","doi-asserted-by":"crossref","first-page":"52841","DOI":"10.1074\/jbc.M310425200","article-title":"Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a)","volume":"278","author":"Edelstein","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib27","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/cvr\/cvab060","article-title":"Apolipoprotein B is an insufficient explanation for the risk of coronary disease associated with lipoprotein(a)","volume":"117","author":"Trinder","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0735-1097(02)02769-9","article-title":"Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes","volume":"41","author":"Tsimikas","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib30","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","article-title":"Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study","volume":"27","author":"Kiechl","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib31","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jacc.2010.04.048","article-title":"Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events","volume":"56","author":"Tsimikas","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib32","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.108.836940","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race\/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study","volume":"119","author":"Tsimikas","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib33","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.atherosclerosis.2009.09.077","article-title":"The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles","volume":"209","author":"Arai","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib34","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1161\/ATVBAHA.115.305306","article-title":"Heritability of biomarkers of oxidized lipoproteins: twin pair study","volume":"35","author":"Rao","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/bmm.11.60","article-title":"Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events","volume":"5","author":"Taleb","year":"2011","journal-title":"Biomarkers Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib36","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib37","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.jacc.2006.03.001","article-title":"Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study","volume":"47","author":"Tsimikas","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib38","first-page":"13","article-title":"Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role","volume":"31","author":"Tselepis","year":"2018","journal-title":"J Biomed Res"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2741\/4377","article-title":"Lysophospholipids and their G protein-coupled receptors in atherosclerosis","volume":"21","author":"Li","year":"2016","journal-title":"Front. Biosci."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib40","doi-asserted-by":"crossref","first-page":"31151","DOI":"10.1074\/jbc.270.52.31151","article-title":"Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein","volume":"270","author":"Blencowe","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib41","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/01.ATV.0000280571.28102.d4","article-title":"New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease","volume":"27","author":"Tsimikas","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib42","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0021-9150(96)05872-8","article-title":"PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro","volume":"125","author":"Karabina","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2004.07.030","article-title":"Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease","volume":"177","author":"Tsironis","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib45","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2013.05.105","article-title":"Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization","volume":"63","author":"Mahmut","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib46","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.cmet.2011.02.016","article-title":"Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium","volume":"13","author":"Zhou","year":"2011","journal-title":"Cell Metabol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib47","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","article-title":"Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve","volume":"132","author":"Bouchareb","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/joim.12519","article-title":"Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease","volume":"280","author":"Nsaibia","year":"2016","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib49","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1161\/01.CIR.0000130844.01174.55","article-title":"Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein","volume":"109","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib50","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1399-0004.1997.tb04342.x","article-title":"Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study","volume":"52","author":"Berg","year":"1997","journal-title":"Clin. Genet."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib52","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1194\/jlr.M060210","article-title":"Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a)","volume":"56","author":"Scipione","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib53","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1096\/fj.08-122002","article-title":"The oxidized phospholipids linked to human apolipoprotein(a) do not derive from circulating low-density lipoproteins and are probably of cellular origin","volume":"23","author":"Edelstein","year":"2009","journal-title":"Faseb. J."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib54","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1021\/bi010964i","article-title":"Comparative analyses of the lysine binding site properties of apolipoprotein(a) kringle IV types 7 and 10","volume":"41","author":"Rahman","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/bi048156p","article-title":"Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10","volume":"44","author":"Belczewski","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib56","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.bbadis.2007.04.009","article-title":"Oxidized phospholipids: from molecular properties to disease","volume":"1772","author":"Fruhwirth","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib57","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib58","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1074\/jbc.270.11.6227","article-title":"Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a)","volume":"270","author":"Ernst","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib59","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2022.04.004","article-title":"Lipoprotein(a): an Underestimated Inflammatory Mastermind","volume":"349","author":"Dzobo","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib61","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cmet.2010.09.010","article-title":"Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress","volume":"12","author":"Seimon","year":"2010","journal-title":"Cell Metabol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib62","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1161\/CIRCULATIONAHA.120.052023","article-title":"Long noncoding RNA MIAT controls advanced atherosclerotic lesion formation and plaque destabilization","volume":"144","author":"Fasolo","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib63","doi-asserted-by":"crossref","first-page":"30503","DOI":"10.1074\/jbc.M802648200","article-title":"Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho\/Rho kinase\/MYPT1-dependent pathway","volume":"283","author":"Cho","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib64","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1091\/mbc.e12-08-0637","article-title":"Apolipoprotein(a) stimulates nuclear translocation of beta-catenin: a novel pathogenic mechanism for lipoprotein(a)","volume":"24","author":"Cho","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib65","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.119.316206","article-title":"Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation","volume":"126","author":"Schnitzler","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib66","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib67","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib68","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/14779072.2017.1367286","article-title":"Pathobiology of Lp(a) in calcific aortic valve disease","volume":"15","author":"Mathieu","year":"2017","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib69","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1172\/JCI119565","article-title":"Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice","volume":"100","author":"Boonmark","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib70","doi-asserted-by":"crossref","first-page":"12591","DOI":"10.1073\/pnas.95.21.12591","article-title":"Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice","volume":"95","author":"Lou","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib71","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI119671","article-title":"Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus","volume":"100","author":"Hughes","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2022.04.001_bib72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and Cardiovascular and Valvular Diseases: a Genetic Epidemiological Perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022001678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022001678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:49:17Z","timestamp":1758156557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022001678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":72,"alternative-id":["S0021915022001678"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.001","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}